Citadel Advisors’s Pactiv Evergreen Inc. Common stock PTVE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
– Sell
-95,600
Closed -$1.72M – 15793
2025
Q1
$1.72M Buy
95,600
+69,600
+268% +$1.24M ﹤0.01% 5827
2024
Q4
$454K Buy
26,000
+18,500
+247% +$250K ﹤0.01% 8771
2024
Q3
$86.3K Sell
7,500
-4,700
-39% -$53.9K ﹤0.01% 11315
2024
Q2
$138K Buy
12,200
+5,400
+79% +$71.8K ﹤0.01% 10467
2024
Q1
$97.4K Buy
6,800
+2,300
+51% +$32.6K ﹤0.01% 11393
2023
Q4
$61.7K Buy
4,500
+3,400
+309% +$35.8K ﹤0.01% 11563
2023
Q3
$8.94K Sell
1,100
-100
-8% -$817 ﹤0.01% 13154
2023
Q2
$9.08K Buy
1,200
+900
+300% +$6.87K ﹤0.01% 13272
2023
Q1
$2.4K Sell
300
-9,800
-97% -$101K ﹤0.01% 14153
2022
Q4
$115K Sell
10,100
-700
-6% -$7.64K ﹤0.01% 11029
2022
Q3
$94K Buy
+10,800
New +$112K ﹤0.01% 11148

Citadel Advisors's PTVE Position: Q2 2025 in Review

Citadel Advisors sold out of Pactiv Evergreen Inc. Common stock (PTVE) in Q2 2025, closing a stake of 132,475 shares — an estimated $2.39M sold.

Citadel Advisors first reported a position in PTVE in Q3 2020 and held it in 17 quarters. The position peaked at $2.41M in Q2 2023. 0 funds tracked by Wall St. Rank hold PTVE as of Q2 2025.

  • Citadel Advisors reported no remaining Pactiv Evergreen Inc. Common stock position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 132,475 Pactiv Evergreen Inc. Common stock shares in Q2 2025, an estimated $2.39M.
  • Citadel Advisors first reported a position in Pactiv Evergreen Inc. Common stock in Q3 2020 and held it in 17 quarters.
  • Citadel Advisors's Pactiv Evergreen Inc. Common stock position peaked at $2.41M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held Pactiv Evergreen Inc. Common stock as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.